Equillium Inc

-0.23 (-5.90%)
Regulatory, Other Pre-Announcement

Equillium Announces Positive Topline Results From The EQUATE Study In First-Line Treatment Of Acute Graft-Versus-Host Disease

Published: 06/11/2021 11:22 GMT
Equillium Inc (EQ) - Equillium Announces Positive Topline Results From the Equate Study in First-line Treatment of Acute Graft-versus-host Disease.
Equillium Inc - Itolizumab Continues to Demonstrate Favorable Safety and Efficacy Profile.
Equillium Inc - Rapid and Durable Responses Resulted in Clinically Meaningful Reduction in Corticosteroid Use.
Equillium Inc - Itolizumab Has Been Well Tolerated in Study and Adverse Events Have Been Consistent With Those Common in High-risk Agvhd.
Equillium Inc - Expects to Engage With Regulatory Agencies in Mid-2021 to Discuss Co's Plans to Proceed With a Pivotal Study in First-line Agvhd.